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SUMMARY 
Background: Mutations in the ganglioside-induced-differentiation-associated-protein 
1 (GDAP1) gene have been reported in Charcot Marie Tooth (CMT) patients, most of 
which have a recessive form of inheritance.  So far, only a few families with 
autosomal dominant (AD) inheritance have been reported and the phenotype is not 
fully characterized.  
Methods: A systematic search for GDAP1 mutations was performed in a large 
clinically well characterized CMT series in which mutations in the most prevalent 
genes involved in CMT had been excluded. All patients were clinically evaluated, and 
neurophysiological studies, muscle magnetic resonance imaging (MRI), and sural 
nerve biopsy were performed when possible.  
Results: We identified 4 unrelated families (17 patients) with the same causative point 
mutation in the GDAP1 gene (p.R120W) which was inherited as an AD trait. 
The clinical picture included a mild-moderate phenotype with onset around 
adolescence, but a great clinical heterogeneity, ranging from elderly asymptomatic 
patients to others in which independent deambulation is difficult. Consistently, ankle 
dorsiflexion and plantar flexion were impaired to a similar degree. Nerve conduction 
studies were compatible with an axonal neuropathy. MRI studies demonstrated 
selective involvement of intrinsic foot muscles in all patients and a uniform pattern of 
fatty infiltration in the calf, with distal and superficial posterior predominance. 
Pathologic data was similar to recessive GDAP1 mutations. 
Conclusions: This work extends the understanding of the pathogenesis of GDAP1 
associated CMT and suggests that mutations in this gene should also be considered in 
patients with CMT2 phenotype independently of the inheritance pattern and severity 
of the disease. 
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INTRODUCTION 
Charcot- Marie-Tooth disease (CMT) is a genetically heterogeneous group of 
inherited motor and sensory neuropathies. Molecular studies have shown extensive 
genetic heterogeneity in CMT neuropathies with an evergrowing list of causative 
mutations and loci.1  Mutations in the ganglioside-induced-differentiation-associated 
protein 1 (GDAP1) gene 8q21 have been reported in CMT patients with 
demyelinating (CMT4A) 2 and axonal forms (CMT2K and ARCMT2K) of the 
disease.3 Inheritance in most causative GDAP1 mutations is autosomal recessive, 4-6 
characterized by a severe phenotype with early disease onset and rapid progression to 
important disability in the second or third decade. In recent reports certain mutations 
have been shown to segregate as an autosomal dominant trait with a later disease onset 
and a mild phenotype4,7,8 being the p.R120W missense mutation the most prevalent 
one.4,9
The utility of muscle MRI in CMT is still to be defined, being a potentially useful 
method for identifying areas of muscle atrophy and fatty infiltration that occur 
secondary to denervation. The presence of high signal intensity within skeletal muscle 
on T2-weighted images, and short tau inversion recovery (STIR) in the correct clinical 
context are suggestive of denervated muscles.10,11 The main objective is to describe a 
characteristic pattern of muscle involvement that can be correlated with the different 
phenotypes and/or genotypes.  
To achieve a complete phenotypic characterization of patients with autosomal 
dominant p.R120W mutation in the GDAP1 gene we provide extensive clinical and 
electrophysiological data, as well as muscle magnetic resonance images from a series 
of 17 CMT patients belong to 4 unrelated families.  
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PATIENTS AND METHODS 
Subjects 
A systematic search for GDAP1 mutations was performed in a large clinically well 
characterized CMT series in which mutations in the most prevalent genes involved in 
CMT (PMP22, MPZ and GJB1), had been excluded independently of the observed 
phenotype. In CMT2 patients mutations in the MFN2, NEFL, MPZ, GJB1 and LITAF 
genes were also discarded. We identified 17 patients from 4 unrelated families with 
GDAP1 mutations in which disease appeared to be inherited as an autosomal 
dominant trait. All protocols performed in this study complied with the ethics 
guidelines of the institutions involved. The pedigrees are displayed in figure 1. 
 
Mutation analysis 
Blood samples were drawn from the patients and relatives after informed consent and 
in accordance with the Helsinki declaration. Genomic DNA was obtained by standard 
methods from peripheral white blood cells. Mutation analysis of the GDAP1 gene was 
performed by amplification of the 6 exons and their intronic flanking sequences using 
primers previously described.3 The PCR products were analyzed by DHPLC 
(Denaturing High Liquid Chromatography, Transgenomic WAVE® System) and the 
anomalous patterns were investigated by automated sequencing (ABI Prism 3130xl, 
Applied Biosystems). When possible, segregation analyses were performed. 
 
Clinical assessments 
All probands and individuals at-risk were examined except patients B-II3 and B-III2. 
The clinical assessment included strength, muscle atrophy, sensory loss, reflexes, foot 
deformities as well as a general and neurologic examination. Muscle strength was 
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graded using the standard Medical Research Council (MRC) scale. CMT neuropathy 
score (CMTNS) was applied to determine neurological impairment: mild 
(CMTNS<10 points), moderate (CMTNS 11–20) and severe (CMTNS 21–36).12 The 
functional disability scale (FDS) 13 was used to measure the disability caused by the 
disease. The data of family B had been partially reported previously.4
 
Electrophysiological studies 
Electrophysiological studies were performed in 14 of the patients. Nerve conduction 
studies (NCS) were tested with surface electrodes. Amplitudes of compound muscle 
action potentials (CMAPs), distal latency (DL) and conduction velocity from median, 
ulnar, peroneal, tibial and axillary nerves were recorded using conventional methods. 
Recordings of sensory nerve action potentials (SNAPs) from median and ulnar nerves 
were performed orthodromically while sural nerve was tested antidromically. 
Concentric needle electromyography was performed in the proximal and distal 
muscles of the upper and lower limbs. 
 
Magnetic resonance imaging 
MRI was performed on the feet and distal legs of 8 patients in a supine position using 
a 1.5 T MR platform (Siemens Avanto, Erlangen, Germany). The following protocol 
was used in all patients: axial and coronal T1-weighted TSE (turbo spin echo), STIR, 
and T1 fat-saturation images before and after Gadolinum-DTPA (Magnevist, 
Schering, Germany) administration were obtained of both legs and feet. Only one 
imaging plane was acquired in each region after contrast administration. 
The four classic anatomical compartments were used to evaluate calf muscles: anterior 
compartment (tibialis anterior, extensor hallucis longus, and extensor digitorum 
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longus), lateral compartment (peronei longus and brevis), superficial posterior 
compartment (soleus and gastrocnemius), and deep posterior compartment (tibialis 
posterior, flexor digitorum longus and flexor hallucis longus). In axial MR images of 
lower limbs, fatty infiltration was graded from 0 to 4 as follows: 0, no fat signal in 
muscle; 1, some fatty streaks; 2, fat occupying a minor part of muscle; 3, similar 
amount of fat and muscle tissue; 4, fat occupying the greater part of muscle.13 
 
Nerve biopsies 
Sural nerve biopsy was performed in two cases (patients A-II1 and C-II2) when they 
were 47 and 31 years old respectively, and compared to a 27 year-old multiorgan 
donor without neuropathic or systemic disease history. Semi-thin sections stained with 
toluidine blue were prepared for evaluation under a light microscope following the 
same protocol as described previously.6 Morphometry of myelinated fibres was 
performed on high-resolution micrographic images obtained with a Polaroid DMC 
digital camera and analyzed by means of Scion image analyst software 
(http://www.scioncorp.com). Ultra-thin cut samples were contrasted with uranyl 
acetate and lead citrate for ultrastructural study.6
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RESULTS 
Mutation analysis 
17 patients from four unrelated families carrying the GDAP1 p.R120W mutation in a 
heterozygous state were identified. No other pathogenic mutations were identified in 
other exons or in their flanking intron regions. Autosomal dominant inheritance was 
confirmed by co-segregation of the GDAP1 p.R120W mutation with disease in these 
four families. 
 
Clinical findings 
The clinical characteristics of 15 patients from the four families with the p.R120W 
missense mutation in the GDAP1 gene are summarized in table 1. 
The age in which patients experienced the first symptom ranged between 9 and 65 
years (median 17 years), with disease duration between 5 and 48 years. There was no 
delay in the acquisition of motor milestones. Four patients (A-II2, A-II3, B-III1 and 
C-I2) aged 20, 38, 33 and 72 did not complain of any symptom but clinical 
examination revealed minor signs. Patient A-II2 had mild weakness in toe extension, 
hyporreflexia and hypoesthesia in lower limbs, patient A-II3 absent ankle reflexes and 
distal hypoesthesia, patient B-III1 pes cavus, and patient C-I2 absent knee and ankle 
jerks.  
The disease started in the distal lower limbs. Only two patients had mild proximal 
involvement in the lower limbs (A-I1 and D-II1), being quite disabling in one case. 
All symptomatic cases presented weakness in ankle plantar flexion (EHL) and toe 
extension. Weakness in ankle dorsiflexors was present to the same degree as plantar 
flexors in most symptomatic patients, being the impairment of heel and toe walk quite 
analogous. Distal upper limb weakness appeared later in the course of the disease and 
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involved the intrinsic hand muscles predominately. At the time of the examination, 12 
patients had motor deficits in distal lower limbs, 7 patients in both the distal lower and 
upper limbs. In one patient (C-II2), the distribution of muscle atrophy and weakness in 
the lower limbs was asymmetric. Proximal muscle strength was abnormal in lower 
limbs in 2 patients. All patients except two had preserved reflexes in the upper limbs, 
but hypo/arreflexia in lower limbs and different degrees of lower limb distal atrophy. 
Foot deformities, including pes cavus and Achilles tendon shortening were also very 
common. Sensory loss proportional to the motor deficit was present in all 
symptomatic patients, especially pinprick and vibration in distal lower limbs. 
The CMTNS scores in the series reflected the wide phenotypic spectrum, ranging 
from 0-25. There were only two patients that were catalogued in the CMTNS severe 
category, both of which had a long disease evolution. Nine patients (60%) were in the 
mild category and 4 in the moderate. All patients to date have a functional disability 
scale equal or less than 4 except two patients, patient A-I1 who is mostly wheelchair 
bound, and patient D-II1 who needs a cane or crutches to walk. Disease progression 
was slow in the majority of cases but two patients (A-I1 and B-I4) had onset after 40, 
but developed a relevant functional impairment. 
 
Electrophysiological studies 
Table 2 summarizes the nerve conduction and electromyography studies performed. 
Motor nerve conduction velocities, distal latencies and f waves were normal in all 
tested nerves (median MNCV > 54 m/sec in all patients). Ulnar and median CMAP 
were reduced only in two individuals, but peroneal CMAP was reduced in most 
affected individuals. Sensory nerve conduction was altered in all patients, with a 
reduction of SNAP, but normal conduction velocities and distal latencies in the tested 
                                                                                                                                                                     10 
nerves with SNAP > 0.5 µv. In all patients, even if asymptomatic, needle 
electromyography revealed MUAPs (motor unit action potentials) increased in 
amplitude, duration and polyphasic incidence. Positive sharp waves and fibrillation 
potentials were not present. 
 
MRI studies 
All patients had detectable abnormalities in the MRI consisting in fatty infiltration 
and/or muscle edema (table 2).  
Intrinsic musculature of both feet showed consistent and bilateral fatty infiltration of 
the foot muscles in all patients, even in asymptomatic ones (figure 2A). The changes 
were present in all intrinsic foot muscles and were more pronounced in severely 
affected patients. All patients had evidence of varying degrees of fatty substitution in 
the muscles of the calf in concordance with the severity of the phenotype. In any case 
there was a common pattern: a predominance of fatty substitution distally and in the 
posterior compartment over the anterolateral one.  
Mild cases showed distinct abnormalities in the distal muscles of the calf; high signal 
intensity on T1-weighted and STIR images, corresponding with fatty substitution and 
muscle edema respectively. The muscle affected first and to a greater degree was the 
gastrocnemius and to a slightly lesser degree the soleus (figure 2B), being the rest of 
the muscles in the calf completely preserved in most mild cases.  
In more severe cases the fatty substitution involved all muscle compartments of the 
calf and muscle edema was no longer present. The posterior compartment was always 
affected to a greater degree than the anterolateral one with a mean grade of 3.1 vs. 1.5 
(p<0.05) (figure 2C). MRI of the thigh was performed in only 2 patients (A-II1 and D-
II1) with a moderate-severe phenotype, existing fatty substitution distally in all the 
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muscles. 
 
Pathologic findings 
The two sural nerves biopsies performed revealed similar pathological findings.  
Semi-thin sections showed a pronounced depletion of myelinated fibres in both nerves 
(fibre density was 3202/mm2 in patient A-II1, 5863/mm2 in patient C-II2, and 
9095/mm2 in the control subject). The histograms of myelinated fibre size were 
‘shifted to the left’ showing a marked reduction of large-diameter fibres especially in 
patient A-II1 (the proportion of fibre size>6 µm was 12,3 % in A-II1, 31,5% in C-II2 and 
41,7% in control )  (figure 3A). Morphometric data also revealed a decrease in myelin 
thickness in proportion to the axonal diameter with a high proportion of fibres with a 
g-ratio > 0.7 (18.2% in A-II1, 20.9% in C-II2 and 5% in control). 
Rather frequent regenerative clusters and occasional onion bulb formations were also 
present (figure 3B). In detailed electron-microscope views, onion bulbs were made up 
of concentric layers of Schwann cell processes adopting a crescent shape that included 
some amyelinic fibers. These formations enclosed a center composed of a regenerative 
cluster or less frequently a hypomyelinated or normally myelinated fibre (fig 3C). 
These formations had a limited number of folds (pseudo-bulbs) not reaching the size 
observed in CMT1A. The regenerative clusters were composed of a group of small 
myelinated fibres, a large bundle of unmyelinated axons or a combination of the two 
(figure 3F).  
On high magnification, myelin compaction always appeared normal. However, axons 
often presented degenerative features consisting on axolemma retraction with  partial 
or total detachment  (fig3D), aggregation of normal and abnormal  mitochondrial 
mixed with empty vacuoles, and cytoskeleton dissolution with early disappearance of 
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microtubules (figure 3E). Degeneration involved both myelinated and unmyelinated 
axons with preference for those included in regenerative clusters (figure 3F). 
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DISCUSSION 
Autosomal dominant GDAP1 mutations are exceedingly rare in most published CMT 
series. Here we present the clinical records belonging to 17 carriers of the GDAP1 
p.R120W mutation from four families.  
The clinical picture comprehends a mild-moderate phenotype with great clinical 
heterogeneity. Disease onset varies, and duration is not clearly related to phenotypic 
severity. The identification of four asymptomatic mutation carriers, one of whom was 
already age 72, suggests that the p.R120W mutation may have incomplete penetrance. 
Weakness is first manifested distally in the lower limbs with the peculiarity that ankle 
dorsi and plantar flexors were impaired in similar degrees, as were tiptoe and heel 
walking. This picture contrasts with the typical CMT1A patients, which usually begin 
with foot drop due to weakness of ankle dorsiflexors,13  being more similar to patients 
with late onset MFN2 (mitofusin 2) mutations (CMT2A) in  which there may exist a 
predominance of ankle plantar flexion weakness and greater difficulty in toe than in 
heel walking.14 
Comparing the distribution of motor weakness in autosomal dominant patients with 
patients carrying recessive GDAP1 mutations is quite a difficult task, due to the 
severity and the rapid disease progression in the latter. In our series with recessive 
GDAP1 mutations,6,15 characterization of the distal distribution weakness has been 
possible only in 2 who had a slightly more indolent course. In these patients the motor 
weakness in ankle plantar and dorsiflexion was similar, as was the impairment of toe 
and heel walking, findings quite analogous to the dominant forms. None of the 
dominant patients had stridor or voice hoarseness, a common characteristic in 
recessive forms.5, 6,15-18  Proximal muscles were involved late in the course of the 
disease in some patients, causing impairment of independent ambulation.   
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Nerve conduction studies in our series revealed motor velocities in the axonal range 
with mildly reduced or normal CMAP amplitudes. Needle electromyography exposed 
giant motor units even in asymptomatic patients. This finding was very consistent in 
our series and has been already described in another family with the p.C240Y 
dominantly inherited mutation in GDAP1.8 The physiopathology of this remains 
unclear, but is consistent with the slowly progressive nature of disease permitting 
significant collateral sprouting and hence motor unit remodelling. 
The pathologic study of the two sural nerve biopsies performed was quite 
homogeneous and very similar to those described in the recessive GDAP1 mutations, 
although the fiber loss was clearly more prominent in recessive forms.6. The main 
abnormalities were, loss of myelinated fibres and axonal degenerative features.  The 
presence of regenerative clusters was prominent, and may represent a true reparative 
process of sprouting after axonal damage, or a developmental abnormality. Whatever 
the origin, these sprouted fibres could account for the high proportion of 
hypomyelinated fibres in the morphometric data. The presence of the small onion bulb 
formations is not yet explained, but probably do not correspond to a purely 
demyelinating phenomenon, as the conduction velocities are clearly in the axonal 
range and the same findings have been reported in other axonal neuropathies like 
MFN2mutations.19 
In our series, the pattern of muscle abnormalities in MRI was quite homogeneous and 
concordant with disease severity. The main abnormalities described in these patients 
are fatty substitution of affected muscles, atrophy and occasionally edema (in subacute 
muscle denervation). The first muscles affected were the intrinsic foot and distal calf 
muscles, with a clear predominance of the posterior over the anterolateral 
compartment. This pattern is the same as that reported in CMT2A,14 and quite 
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different from CMT1A20 where there is a predominance of fatty substitution in the 
anterolateral compartment of the calf. 
Most of GDAP1 mutations co-segregate with CMT in an autosomal recessive 
manner,2-6, 15-18  whereas autosomal dominant GDAP1 mutations are rare. Mutations 
causative of an axonal CMT neuropathy with both dominant and recessive patterns of 
inheritance have been reported in three other genes: NEFL,21-22 HSP223 and MFN2.24-
25 To date six GDAP1 missense mutations with autosomal dominant inheritance 
pattern have been described: p.R120W, p.T157P, p.Q218E, p.C240Y, p.P274L and 
p.H123R.4,7-9 Each of these mutations have been described in only one family except 
the p.R120W and the p.H123R changes: p.H123R has been identified in CMT patients 
from two unrelated families,9 and p.R120W in six unrelated families including the 
present work.4,9 The p.R120W mutation has been also described in a compound 
heterozygous CMT patient carrier of both p.R120W and p.G217R mutations in a 
heterozygous state.26 This patient had a severe phenotype similar to the autosomal 
recessive GDAP1 mutations. The p.R120W substitution was transmitted from his 
deceased father and unfortunately, clinical symptoms from him are not referred, 
therefore, he might have suffered a mild clinical picture or be an asymptomatic 
carrier. 
GDAP1 is a mitochondrial fission protein localized in the mitochondrial outer 
membrane, functioning as a tail-anchored protein 27-30 that promotes fission without 
increasing the risk of apoptosis.31 Little is known about how GDAP1 mutations affect 
the proper function of the protein, and different malfunction in mitochondrial 
dynamics have been postulated according to the mode of inheritance.  Recessive 
GDAP1 mutations seem to lead to a reduction of fission activity whereas dominant 
GDAP1 mutations may impair mitochondrial fusion and cause mitochondrial 
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aggregation. This latter mechanism may be similar to some pathogenic MFN2 
mutations (CMT2A) in which its mitochondrial fusion activity is not overly affected, 
but there is excessive mitochondrial aggregation and impairment of mitochondrial 
transport. 31-33 This observation emphasizes that both GDAP1 and MFN2 may be 
involved in the same pathway of axonal CMT pathophysiology, explaining the clinical 
and neuroimaging similarities.   
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FIGURES & LEGENDS 
Figure 1. Pedigrees of the 4 affected families 
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Figure 2 MRI of the foot and calf muscles in mild and severe phenotypes 
 
 
 
 
 
 
 
 
 
 
 
A 
B 
 
C 
A) Axial T1 weighted images showing fatty infiltration in the intrinsic foot muscles 
from left to right of a control subject, an asymptomatic patient (patient A-II2) and a 
moderately severe patient (patient C-II2).  
II  
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B) Axial STIR (above) and T1 weighted (below) images of the calf of patients with a 
mild phenotype (patient C-I2 & B-II1 respectively). There is muscle edema and fatty 
infiltration in the superficial posterior compartment of the calf (arrows).  
C) Axial T1 weighted images of the calf (left) and thigh (right) of patients with a 
severe phenotype (patient A-I1 & D-II1 respectively) showing  fatty substitution in all 
the muscle compartments of the calf (posterior > anterolateral) and distal thigh. 
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Figure 3 
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Figure 3. 
 A) Histograms representing myelinated fibre distribution of patients A-II1 and 
C-II2 (filled bars). Note the predominant loss of large myelianted fibres 
compared with a control subject (open bars).  
B) Semi-thin transverse section of Patient A-II1 showing a pronounced 
depletion of large myelinated fibres, and myelin thickness, as well as 
regenerative clusters and few onion bulb formations.  
Plates C to F display distinct electron microscope views. C) Onion bulb 
formation surrounding a thinly myelinated axon. D) Axonal atrophy with 
axolemma detachment from myelin sheath. E) Normally myelinated axon with 
focal accumulates of abnormal mitochondria and paucity of microtubules. 
 F) Bulb formation encircling a regenerating cluster of unmyelinated axons.  
G) Regenerative cluster composed of a bundle of axons, one of them with a 
tiny myelin sheath, showing axoplasmic degenerative features.  
Bar= 10 µm in B, 2 µm in C, D, F, G, 1 µm in E 
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Table 1.Clinical data of the series 
Patient 
Age at 
exam./ 
Onset (ys)
CMTNS Proximal LL 
Ankle 
DF 
Ankle 
PF 
TE  IHM
Heel/
Toe 
walk 
UL 
DTR 
Knee 
DTR 
Ankle 
DTR 
Pes 
cavus 
Pinprick 
sesory loss  
Vibratory 
sensory loss FDS 
A-I1                67/>40 21 4 2 2 0 4 I/I + - - moderate knee/elbow ankle 5
A-II1                43/9 14 5 3 3 0 4+ I/I ++ + - moderate knee/elbow ankle 3
A-II2                40/A 5 5 5 5 4+ 5 N/D ++ ++ + mild toes none 0
A-II3                38/35 7 5 5 5 5 5 N/N ++ ++ - mild ankle toes 0
B-I4                 80/65 11 * 5 2 2 2 4 I/I - - - no ankle ankle 4
B-II1                52/15 10 5 4 4 3 4 I/I ++ ++ - mild ankle none 3
B-III1                20/A 0 5 5 5 5 5 N/N ++ ++ ++ mild none none 0
B-II2                40/16 4 5 4 5 4 5 D/D ++ + - mild ankle toes 1
B-II4                38/17 12 5 4 4 3 4 D/D ++ + - moderate ankle toes 3
C-I1                62/18 9 5 5 4 3 5 D/D ++ - - moderate ankle/finger ankle 2
C-II1                33/20 6 5 5 5 5 5 D/N ++ - - mild ankle none 1
C-II2               30/14 15 5 3 2R/4L 1 4 I/I ++ - - moderate ankle ankle 2
C-II3                24/12 7 5 4 4 3 5 D/D ++ + - moderate ankle none 2
C-I2                 72/A 0 * 5 5 5 5 5 N/N ++ - - no none none 0
D-II1              75/25 25 4+ 0 0 0 4 I/I - - - mild knee/finger ankle 5 
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A: asymptomatic, * : Patients in which only the clinical parameters were used to calculate the CMTNS score (no electrophysiological data 
available), LL= lower limbs, DF= dorsiflexion, R = right, L = left, PF= plantar flexion, TE = toe extension, IHM= intrinsic hand muscles. I= 
impossible, D= difficulty, N= normal, UL = upper limbs, DTR = deep tendon reflexes.  
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Table 1.Nerve conductions and MRI data 
Nerve conduction studies MRI 
Median     Ulnar Peroneal Median Sural
Patient CMAP 
mv 
MCV 
m/s 
CMAP 
mv 
MCV 
m/s 
CMAP 
mv 
MCV 
m/s 
SNAP 
µv 
SCV 
m/s 
SNAP 
µv 
SCV 
m/s 
IFM 
 
Soleus 
Gastroc- 
nemius 
DPC    AC LC Thigh
A-I1                  9,4 54,8 6,1 53,5 0,6 40,3 1,6 36,3 NR NR - - - - - - -
A-II1                7,5 69 NP NP 1,3 48 4 44 3 29 4 4 4 2 3 3 3 
A-II2                  9,5 60 12 60,3 5,4 42 12 57,1 1,8 50 3 2 3 0 0 1 -
A-II3                  11,5 60 15,7 64,9 7,3 50,8 10 54,7 9,1 NP 2 1 1 0 0 0 -
B-II1                  11,2 69,1 11,7 67,9 4 53,7 6,5 53,3 6,2 55,6 - - - - - - -
B-III1                  17,2 61,2 20,6 69,3 11,9 45 24 50 15 65,9 - - - - - - -
B-II2                  12,1 60,3 14,4 52,3 4 43,8 26 60 9,9 48,2 - - - - - - -
B-II3                  9,1 59 NP NP 1,8 47 8,5 49 0,5 41 - - - - - - -
B-II4                  11,7 56,5 13,6 57,5 2,1 40,8 2,8 47,4 6,6 33,3 - - - - - - -
C-I1                  NP NP NP NP 7,9 42,5 NR NR 1,1 37,6 4 3 4 0 1 1 -
C-II1                  18,5 57 NP NP 15 39 4,5 NP 0.7 - - - - - - - -
C-II2                  15 56,3 13,7 59,2 0,5 - 5,8 40,7 4,5 38,2 4 4 4 1 2 2 -
C-II3                  8 56 NP NP 5,2 45 1,6 - NR NR 4 4 4 1 1 1 -
C-I2                  - - - - - - - - 3 1 2 0 0 1 -
D-II1                  6.6 53.8 5.6 50 NR NR NR NR 0.7 37.1 4 4 4 3 4 4 3
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 CMAP= compound muscle action potential, MCV= motor nerve conduction velocity, SCV= sensory conduction velocity, SNAP= compound 
sensory nerve action potential. NP= not performed; NR= no response, IFM= intrinsic foot muscles, DPC= deep posterior compartment, AC= 
Anterior compartment, LC= lateral compartment. 
 
 
